Targets › SLC19A2
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Oct 2027.
High-affinity transporter for the intake of thiamine. Mediates H(+)-dependent pyridoxine transport. (UniProt, O60779)
Open in Phaseline: the race on SLC19A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | Thiamine Thiamine supplementation to reduce brain injury and cognitive impairment associated with c | SLC19A2, SLC19A3 | Phase 2 | Alcohol Use Disorder | Oct 2027 |
Alcohol Use Disorder (1)
small molecule (1)
Institut National de la Santé Et de la Recherche Médicale, France (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.